Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study

2013 ◽  
Vol 70 (1) ◽  
pp. 99-108 ◽  
Author(s):  
D. Macías Saint-Gerons ◽  
C. de la Fuente Honrubia ◽  
D. Montero Corominas ◽  
M. J. Gil ◽  
F. de Andrés-Trelles ◽  
...  
Keyword(s):  
Primary Prevention ◽  
Vascular Diseases ◽  
Population Based ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Population Based Study ◽  
Lowering Therapy

scholarly journals Lipid-lowering therapy for primary prevention of premature atherosclerotic coronary artery disease: Eligibility, utilization, target achievement, and predictors of initiation

2020 ◽  
Vol 2 ◽  
pp. 100036
Author(s):  
Diana N. Vikulova ◽  
Ilia S. Skorniakov ◽  
Brendon Bitoiu ◽  
Chad Brown ◽  
Emilie Theberge ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Primary Prevention ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Artery Disease

scholarly journals Lipid-Lowering Therapy for Primary Cardiovascular Prevention in Older Adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists

Kardiologiia ◽  
2020 ◽  
Vol 60 (6) ◽  
pp. 119-132
Author(s):  
Y. V. Kotovskaya ◽  
O. N. Tkacheva ◽  
I. V. Sergienko
Keyword(s):  
Primary Prevention ◽  
Statistical Power ◽  
Density Lipoprotein ◽  
Cardiovascular Prevention ◽  
Lipid Lowering ◽  
Russian Society ◽  
National Society ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Age Related

 Completed randomized clinical studies did not have a sufficient statistical power for demonstrating clearly the efficacy of lipid-lowering therapy for primary prevention in patients aged 75 years and older and did not evaluate the effect of lipid-lowering therapy on development and course of key geriatric syndromes. Age-related alterations of skeletal muscles, cognitive decline, senile asthenia, comorbidities, polypragmasy, potential changes in drug pharmacokinetics and pharmacodynamics, and impaired renal function may adversely affect the benefit to harm ratio of statins in older patients. Key questions for administration of a lipid-lowering therapy for primary prevention in patients aged 75 years and older are: 1. Does the relationship between increased low-density lipoprotein cholesterol (LDL CS) and death rate persist? 2. Does a benefit from decreasing the level of LDL CS persist? 3. Is the lipid-lowering therapy safe? 4. What scales for risk stratification and determining indications for lipid-lowering therapy should be used?

A Comparison of Algorithms for Initiation of Lipid Lowering Therapy in Primary Prevention of Coronary Heart Disease

2000 ◽  
Vol 7 (1) ◽  
pp. 63-71 ◽  
Author(s):  
Anthony S. Wierzbicki ◽  
Timothy M. Reynolds ◽  
Kiryat Gill ◽  
Sonia Alg ◽  
Martin A. Crook
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Primary Prevention ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Comparison Of Algorithms

scholarly journals Use of Lipid-lowering Agents in Rheumatoid Arthritis: A Population-based Cohort Study

2013 ◽  
Vol 40 (7) ◽  
pp. 1082-1088 ◽  
Author(s):  
Bharath Manu Akkara Veetil ◽  
Elena Myasoedova ◽  
Eric L. Matteson ◽  
Sherine E. Gabriel ◽  
Cynthia S. Crowson
Keyword(s):  
Rheumatoid Arthritis ◽  
General Population ◽  
Population Based ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Kaplan Meier ◽  
Increased Risk ◽  
Lipid Testing ◽  
Lipid Lowering Agents

Objective.Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease and mortality. Lipid-lowering therapy is reportedly underused in patients with RA. Longitudinal cohort studies comparing use of lipid-lowering medications in patients with RA versus the general population are lacking.Methods.Cardiovascular risk factors, lipid measures, and use of lipid-lowering agents were assessed in a population-based inception cohort of patients with RA and a cohort of non-RA subjects followed from January 1, 1988, to December 31, 2008. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII) guidelines were assessed at the time of each lipid measure throughout followup. Time from meeting guidelines to initiation of lipid-lowering agents was assessed using Kaplan-Meier methods.Results.The study population included 412 RA and 438 non-RA patients with ≥ 1 lipid measure during followup and no prior use of lipid-lowering agents. Rates of lipid testing were lower among patients with RA compared to non-RA subjects. Among patients who met NCEP ATPIII criteria for lipid-lowering therapy (n = 106 RA; n = 120 non-RA), only 27% of RA and 26% of non-RA subjects initiated lipid-lowering agents within 2 years of meeting the guidelines for initiation.Conclusion.There was substantial undertreatment in both the RA and the non-RA cohorts who met NCEP ATPIII criteria for initiation of lipid-lowering agents. Patients with RA did not have as frequent lipid testing as individuals in the general population.

scholarly journals Statins in the primary prevention of cardiovascular disease. Rosuvastatin capabilities

2021 ◽  
Vol 12 (2) ◽  
pp. 110-118
Author(s):  
Marina G. Bubnova ◽  
Marianna Y. Ilchenko ◽  
Petr A. Lebedev
Keyword(s):  
Cardiovascular Risk ◽  
Primary Prevention ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Clinical Results ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Clinical Effects ◽  
Lowering Therapy ◽  
Novel Coronavirus

The article discusses the modern principles of lipid-lowering therapy and approaches to its administration in terms of levels of cardiovascular risk. The characteristics of groups of patients with different levels of cardiovascular risk (from low to high) in primary prevention are given. The article defines the target levels of low- density lipoprotein cholesterol, which should be achieved with the modern lipid-lowering therapy. The clinical effects of statins in primary prevention are presented. The clinical results of two large studies of rosuvastatin that have changed the approach to statin prescribing in primary prevention are discussed. The article presents the results of the analysis of long-term follow-up of patients in the primary prevention after the completion of randomized clinical studies. Approaches to the use of statins for novel coronavirus infection are considered.

scholarly journals Vascular age derived from coronary artery calcium score on the risk stratification of individuals with heterozygous familial hypercholesterolaemia

2019 ◽  
Vol 21 (3) ◽  
pp. 251-257 ◽  
Author(s):  
Marcio H Miname ◽  
Marcio Sommers Bittencourt ◽  
Alexandre C Pereira ◽  
Cinthia E Jannes ◽  
Jose E Krieger ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Primary Prevention ◽  
Coronary Artery Calcium ◽  
Familial Hypercholesterolaemia ◽  
Lipid Lowering ◽  
Lipid Lowering Therapy ◽  
Lowering Therapy ◽  
Vascular Age ◽  
Ascvd Risk ◽  
Heterozygous Familial Hypercholesterolaemia

Abstract Aims The objective of this study was to evaluate if vascular age derived from coronary artery calcium (CAC) score improves atherosclerosis cardiovascular disease (ASCVD) risk discrimination in primary prevention asymptomatic heterozygous familial hypercholesterolaemia (FH) patients undergoing standard lipid-lowering therapy. Methods and results Two hundred and six molecularly confirmed FH individuals (age 45 ± 14 years, 36% males, baseline LDL-cholesterol 6.2 ± 2.2 mmol/L; 239 ± 85mg/dL) were followed by 4.4 ± 2.9 years (median: 3.7 years, interquartile ranges 2.7–6.8). CAC measurement was performed, and lipid-lowering therapy was optimized according to FH guidelines. Vascular age was derived from CAC and calculated according to the Multi Ethnic Study of Atherosclerosis algorithm. Risk estimation based on the Framingham equations was calculated for both biological (bFRS) and vascular (vaFRS) age. During follow-up, 15 ASCVD events (7.2%) were documented. The annualized rate of events for bFRS <10%, 10–20%, and >20% was respectively: 8.45 [95% confidence interval (CI) 3.17–22.52], 23.28 (95% CI 9.69–55.94), and 28.13 (95% CI 12.63–62.61) per 1000 patients. The annualized rate of events for vaFRS <10%, 10–20%, and >20% was respectively: 0, 0, and 50.37 (95% CI 30.37–83.56) per 1000 patients. vaFRS presented a better discrimination for ASCVD events compared to bFRS 0.7058 (95% CI 0.5866–0.8250) vs. vaFRS 0.8820 (95% CI 0.8286–0.9355), P = 0.0005. Conclusion CAC derived vascular age can improve ASCVD risk discrimination in primary prevention FH subjects. This tool may help further stratify risk in FH patients already receiving lipid-lowering medication who might be candidates for further treatment with newer therapies.

Sign in / Sign up

Export Citation Format

Share Document